Ipsen Bioinnovation Limited

Syntaxin Limited

Toxogen Gmbh

Andreas Rummel

Tanja Weil

Aleksandrs Gutcaits

Johannes Wilhelm Bigalke

Thomas Binz

Stefan Mahrhold

Hans Bigalke

Jasmin Weisemann

A proteolytically active polypeptide comprising an acid sequence having at least 50% sequence identity with the sequence of SEQ ID NO: 1 with the proviso that the polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1. A nucleic acid encoding the polypeptide. An antibody specifically binding to the polypeptide. A method for the manufacture of a proteolytically processed polypeptide comprising contacting a first polypeptide having at least 50% sequence identity to SEQ ID NO: 1 with a second polypeptide that is susceptible to proteolysis by said first polypeptide.

Methods for the manufacture of proteolytically processed polypeptides

The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed bywherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

Carrier for targeting nerve cells

The present invention relates to a novel protcolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods.

The present invention relates to a novel proteolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods.

The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.

Transport protein which is used to introduce chemical compounds into nerve cells

The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed bywherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragma assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

The invention relates to an isolated polypeptide of the luminal domain of synaptic vesicle glycoprotein 2C ofwherein at least 70 percent of the amino acid sequence is identical to the amino acid sequence of the SV2C of. The polypeptide binds the Hfragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic vesicle glycoprotein 2C of

Growing community of inventors

Hannover, Germany

Andreas Rummel